High frequency of T cells specific for cryptic epitopes in melanoma patients

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Andersen, Rikke Sick ^a   Andersen, Sofie Ramskov ^a   Hjortsø, Mads Duus ^a   Lyngaa, Rikke ^a   Idorn, Manja ^a   Køllgård, Tania Maria ^a   Met, Özcan ^a   Straten, Perthor ^a   Hadrup, Sine Reker ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antigens; CD8 T cells; Cryptic T cell epitopes; Melanoma; T cell reactivity

Indexed keywords

ALPHA 1,3(6) MANNOSYLGLYCOPROTEIN BETA 1,6 N ACETYLGLUCOSAMINYLTRANSFERASE; ANTIGEN ISOLATED FROM IMMUNOSELECTED MELANOMA 2; EPITOPE; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD; BREAST CARCINOMA; CANCER PATIENT; CONTROLLED STUDY; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MELANOMA; OPEN READING FRAME; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE;

EID: 84886945647     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25374     Document Type: Article

References (22)

1. Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, EllebÆk E, et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res 2012; 72:1642-50; PMID:22311675; http://dx.doi. org/10.1158/0008-5472.CAN-11-2614
2. Harada M, Li YF, El-Gamil M, Ohnmacht GA, Rosenberg SA, Robbins PF.Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.J Immunother 2001; 24:323-33; PMID:11565834; http://dx.doi.org/10.1097/00002371-200107000-00008
3. Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, et al.A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.J Exp Med 1996; 183:1173-83; PMID:8642259; http://dx.doi.org/10.1084/jem.183.3.1173
4. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Liénard D, Lejeune F, et al.High frequencies of naive Melan-A/ MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.J Exp Med 1999; 190:705- 15; PMID:10477554; http://dx.doi.org/10.1084/ jem.190.5.705
5. Rosenberg SA, Tong-On P, Li Y, Riley JP, El-Gamil M, Parkhurst MR, et al.Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy.J Immunol 2002; 168:2402-7; PMID:11859131
6. Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, et al.MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.J Exp Med 2008; 205:2673-82; PMID:18936238; http://dx.doi.org/10.1084/jem.20081356
7. Rubio-Godoy V, Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, et al.Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life.Proc Natl Acad Sci U S A 2001; 98:10302-7; PMID:11517329; http://dx.doi.org/10.1073/pnas.181348898
8. Liu G, Yu JS, Zeng G, Yin D, Xie D, Black KL, et al.AIM-2: a novel tumor antigen is expressed and presented by human glioma cells.J Immunother 2004; 27:220-6; PMID:15076139; http://dx.doi.org/10.1097/00002371-200405000-00006
9. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, et al.Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cellbased therapeutics.Clin Cancer Res 2007; 13:566-75; PMID:17255279; http://dx.doi.org/10.1158/1078- 0432.CCR-06-1576
10. Labarriere N, Diez E, Pandolfino MC, Viret C, Guilloux Y, Le Guiner S, et al.Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription.J Immunol 1997; 158:1238-45; PMID:9013965
11. Gervois N, Guilloux Y, Diez E, Jotereau F.Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.J Exp Med 1996; 183:2403-7; PMID:8642353; http://dx.doi.org/10.1084/jem.183.5.2403
12. Bouquié R, Bonnin A, Bernardeau K, Khammari A, Dréno B, Jotereau F, et al.A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes.Cancer Immunol Immunother 2009; 58:553-66; PMID:18751701; http://dx.doi.org/10.1007/s00262-008-0578-2
13. LabarriÈre N, Bretaudeau L, Gervois N, Bodinier M, Bougras G, Diez E, et al.Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen.Int J Cancer 2002; 101:280-6; PMID:12209980; http://dx.doi.org/10.1002/ijc.10605
14. Nolte A, Scheffold C, Slotty J, Huenefeld C, Schultze JL, Grabbe S, et al.Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy.J Immunother 2003; 26:257-69; PMID:12806279; http://dx.doi.org/10.1097/00002371-200305000-00009
15. Labarriere N, Pandolfino MC, Raingeard D, Le Guiner S, Diez E, Le Dréan E, et al.Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes.Int J Cancer 1998; 78:209-15; PMID:9754654; h t t p : //d x .d o i .o r g /1 0 .1 0 0 2 /( S I C I ) 1 0 9 7 -0215(19981005)78:2209::AID-IJC153.0.CO;2-5
16. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF.Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.Cancer Immunol Immunother 2006; 55:1185-97; PMID:16468035; http://dx.doi.org/10.1007/s00262-005-0118-2
17. Ghosh MK, Li CL, Fayolle C, Dadaglio G, Murphy A, Lemonnier FA, et al.Induction of HLA-A2-restricted CTL responses by a tubular structure carrying human melanoma epitopes.Vaccine 2002; 20:2463-73; PMID:12057601; http://dx.doi.org/10.1016/S0264-410X(02)00185-8
18. Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, LabarriÈre N, et al.Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.Clin Cancer Res 2006; 12:7380-8; PMID:17189411; http://dx.doi.org/10.1158/1078-0432.CCR-06-1879
19. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
20. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al.Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.J Clin Oncol 2005; 23:2346-57; PMID:15800326; http://dx.doi.org/10.1200/JCO.2005.00.240
21. Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, et al.Immunogenicity of Bcl-2 in patients with cancer.Blood 2005; 105:728-34; PMID:15367432; http://dx.doi.org/10.1182/blood-2004-07-2548
22. Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, Valencia G, et al.Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.J Immunol 1999; 163:3812-8; PMID:10490979